A compounding pharmacy that waives a patient's copayment, or hands over a free introductory supply of a compounded drug, is transferring remuneration to a beneficiary of a federal health care program. The Anti-Kickback Statute and the civil beneficiary inducements penalty both treat that transfer as a potential inducement, and a kickback violation converts every claim submitted afterward into a False Claims Act violation. The exposure reaches the pharmacy, the pharmacist in charge, and whoever designed the offer.
The Regulatory Risk Behind a Waived Copay
Compounding pharmacies compete for patients, including those seeking compounded semaglutide and tirzepatide formulations marketed through telehealth platforms, and a waived copay or a free first fill is a low-cost way to win a referral. Medicare, Medicaid, and other federal programs pay the balance of that claim. The HHS Office of Inspector General's May 1991 Special Fraud Alert on routine waiver of Medicare Part B copayments and deductibles treats forgiven cost sharing as suspect. Forgiving a patient's financial obligation for reasons other than genuine financial hardship can unlawfully induce the patient to choose that provider, and a good faith effort to collect the copayment is otherwise required.
The analysis gets more complicated when the waiver is built into a telehealth marketing arrangement for compounded GLP-1 products, where the prescribing platform, the pharmacy, and the marketer can each hold a share of the same remuneration exposure.
A pharmacy already responding to FDA Form 483 observations from an inspection should treat a parallel kickback inquiry as a separate track with its own counsel, not an extension of the same response.
The Anti-Kickback and False Claims Exposure
The Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b)(2), makes it a felony to knowingly and willfully offer or pay remuneration to induce a person to purchase or order any good or service reimbursable under a federal health care program. Conviction carries a fine of up to $100,000, up to ten years in prison, or both. The beneficiary inducements civil monetary penalty at 42 U.S.C. § 1320a-7a(a)(5) reaches the same conduct without requiring criminal intent and authorizes a penalty of up to $20,000 for each item or service involved under the statute, a cap HHS is required to adjust for inflation each year. Because 42 U.S.C. § 1320a-7b(g) makes a claim resulting from an Anti-Kickback Statute violation a false claim for purposes of the False Claims Act, every claim connected to the waived copay or the free fill carries False Claims Act exposure in addition to the kickback exposure itself.
The Narrow Financial Hardship Exception
Both statutes recognize the same narrow opening. The 1991 Special Fraud Alert allows a pharmacy to forgive a copayment because of a particular patient's financial hardship, but states that the exception must not be used routinely. The civil penalty statute codifies the same idea at 42 U.S.C. § 1320a-7a(i)(6)(A), excluding a waiver from the definition of remuneration only when the pharmacy determines in good faith that the individual is in financial need. A waiver advertised to every patient, built into a telehealth intake script, or applied without an individualized financial assessment does not fit the exception. A first-month-free offer that functions the same way does not fit it either.
A waiver offered to every patient who asks is the routine practice the kickback rules were written to stop.
Why Early Legal Counsel Is Critical
Compounding pharmacies should retain experienced healthcare defense counsel promptly after receiving a civil investigative demand, a grand jury subpoena, or any other government inquiry into a copay waiver or a promotional pricing practice. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance has represented 2,500+ clients nationwide.
The firm's compounding pharmacy attorneys represent 503A and 503B pharmacies in Anti-Kickback Statute, beneficiary inducements, and False Claims Act matters that arise from copay and pricing practices, including matters that escalate toward criminal healthcare fraud defense. Pharmacies that have waived copayments routinely, or that are reviewing a promotional pricing practice before a regulator does, should contact us for a free, confidential consultation.
